Department of Neurology and Rehabilitation, Komaki City Hospital, Japan.
Department of General Internal Medicine, Komaki City Hospital, Japan.
Intern Med. 2022 May 15;61(10):1609-1612. doi: 10.2169/internalmedicine.8815-21. Epub 2022 Mar 12.
We herein report a 72-year-old woman with rheumatoid vasculitis who exhibited a depressed level of consciousness after receiving the first dose of the Pfizer-BioNTech mRNA BNT162b COVID-19 vaccine and was diagnosed with meningoencephalitis. Although there was no confirmatory examination, the diagnosis was based on magnetic resonance imaging (MRI) findings and etiological assessments, including microbiological and autoimmune investigations. Both intravenous steroid pulse and gammaglobulin therapies alleviated the patient's symptoms, and the MRI findings improved. Although the efficacy of COVID-19 vaccination has been widely accepted, such neurologic complications might occur in patients with rheumatoid diseases or vasculitis syndromes.
我们在此报告一例 72 岁女性类风湿性血管炎患者，在接种辉瑞-生物科技 mRNA BNT162b COVID-19 疫苗第一针后出现意识障碍，并被诊断为脑膜炎脑炎。虽然没有进行确诊性检查，但该诊断基于磁共振成像（MRI）结果和病因评估，包括微生物学和自身免疫检查。静脉用类固醇脉冲和丙种球蛋白治疗均缓解了患者的症状，MRI 结果也有所改善。尽管 COVID-19 疫苗接种的疗效已得到广泛认可，但类风湿性疾病或血管炎综合征患者可能会发生此类神经系统并发症。
